UroGen Pharma clinical trials we track

Check company identity source

Phase 3 5 trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2027-06-14DayUGN-103UroGen Pharma Ltd. · URGNCompany-disclosed PDUFA goal dateAnnounced review targetrecurrent low-grade intermediate risk NMIBCOpen original source
Read source excerpt

In August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-06-14DayUGN-103UroGen Pharma Ltd. · URGNCompany-disclosed PDUFA goal dateAnnounced review targetadults with recurrent low-grade intermediate risk NMIBCOpen original source
Read source excerpt

Our NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

2027-06-14DayUGN-103UroGen Pharma Ltd. · URGNCompany-disclosed PDUFA goal dateAnnounced review targetrecurrent LG-IR-NMIBCOpen original source
Read source excerpt

In October 2026, the FDA accepted for review UroGen’s NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027. The NDA is based on clinical data from the ongoing Phase 3 UTOPIA trial, a single-arm, multicenter trial evaluating the efficacy and safety of UGN-103 in adult patients with recurrent LG-IR-NMIBC.

First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Complete response rate (CRR) Description: CRR is defined as the proportion of patients who achieved CR at the 3-month Visit. Time frame: 3 months. After: Measure: Complete Response Rate (CRR) Description: CRR is defined as the proportion of patients who achieved a complete response (CR) at the 3-month Visit. A patient was considered a CR if there was no detectable disease in the bladder based on visual observation (white light cystoscopy), biopsy of remaining lesions (if applicable), and voiding urine cytology. Time frame: 3 months.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 92 participants (planned). After: 99 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Aug 2025. After: 11 Sep 2025.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source